@article{059c1dfd2bc94ae2be4183786b614a2d,
title = "Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option",
abstract = "Background: Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options. Design: Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed. Results: Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with results from Gynecologic Oncology Group (GOG) 213 and anticipated results from DESKTOP III clinical trials. Chemotherapy backbone has remained relatively unchanged but utilizing non-platinum-based regimens is under investigation. In addition, maintenance therapy with anti-Angiogenic therapy and Poly (ADP-ribose) Polymerase (PARP) inhibitors has emerged as the standard of care. Novel combinations, including immunotherapy and anti-Angiogenesis agents, may further change the current landscape. Conclusions: The treatment of recurrent EOC is rapidly changing. Clinical trial design will need to continue to evolve as many novel therapies move to the upfront setting. Ultimately, the treatment of patients with recurrent EOC must incorporate individual patient and tumor factors.",
keywords = "maintenance therapy, molecular characterization, ovarian cancer, platinum",
author = "M. Buechel and Herzog, {T. J.} and Westin, {S. N.} and Coleman, {R. L.} and Monk, {B. J.} and Moore, {K. N.}",
note = "Funding Information: MB has no disclosures. TJH reports personal fees from J & J, personal fees from Clovis, personal fees from AstraZeneca, personal fees from Tesaro, personal fees from Roche, personal fees from Caris. SNW reports grants and personal fees from AstraZeneca, grants and personal fees from Clovis, grants and personal fees from Tesaro, grants and personal fees from Roche/Genentech, grants from Cotinga Pharmaceuticals, personal fees from Merck, personal fees from Pfizer, grants from Novartis, personal fees from Takeda, grants from ArQule, outside the submitted work. RLC reports grants from AstraZeneca, Roche/Genentech, Janssen, OncoMed, Merck, Clovis Oncology, Esperance, and AbbVie and reports serving as an advisor to AstraZeneca, Roche/ Genentech, Janssen, OncoMed, Agenus, Incyte, Merck, Clovis Oncology, Esperance, Tesaro, GamaMabs, Pfizer, Genmab, and AbbVie. BJM reports honorarium/consulting for Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Conjupro, Genmab, Gradalis, Immunogen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precision Oncology, Puma, Roche/Genetech, Samumed, Takeda, Tesaro, and VBL. KNM reports advisory board participation and compensation from Astra Zeneca, Genentech/Roche, Merck, Pfizer, Janssen, Immunogen, Clovis, Tesaro, VBL Therapeutics, Aravive, OncoMed, Incyte, Genmab. She reports research grants from PTC Therapeutics, Lilly and Genentech. Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = may,
doi = "10.1093/annonc/mdz104",
language = "English (US)",
volume = "30",
pages = "721--732",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",
}